The immunological effect of hyaluronan in tumor angiogenesis

Clinical and Translational Immunology

Volumn 4, Issue 12, 2015, Pages

  Spinelli, Fiorella M ^a,b   Vitale, Daiana L ^a,b   Demarchi, Gianina ^a,c   Cristina, Carolina ^a,c   Alaniz, Laura ^a,b  

^a Universidad Nacional del Noroeste de la Provincia de Buenos Aires   (Argentina)

^b CIBA   (Argentina)

^c CIBA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; HERMES ANTIGEN; HYALURONIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; TOLL LIKE RECEPTOR 4;

ANGIOGENESIS; EXTRACELLULAR MATRIX; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INTRACELLULAR SIGNALING; NEOPLASM; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT;

EID: 85013158547     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2015.35     Document Type: Review

References (131)

1. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 2011; 27: 563–584.
2. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9 (Suppl 1): 2–10.
3. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2: REVIEWS3005.
4. Cristina C, Luque GM, Demarchi G, Lopez Vicchi F, Zubeldia-Brenner L, Perez Millan MI et al. Angiogenesis in pituitary adenomas: human studies and new mutant mouse models. Int J Endocrinol 2014; 2014: 608497.
5. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003; 9: 713–725.
6. Hagendoorn J, Tong R, Fukumura D, Lin Q, Lobo J, Padera TP et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res 2006; 66: 3360–3364.
7. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC et al. Tumour-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64: 8249–8255.
8. Grover AC, Tangrea MA, Woodson KG, Wallis BS, Hanson JC, Chuaqui RF et al. Tumour-associated endothelial cells display GSTP1 and RARbeta2 promoter methylation in human prostate cancer. J Transl Med 2006; 4: 13.
9. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E et al. Genes expressed in human tumour endothelium. Science 2000; 289: 1197–1202.
10. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071–1121.
11. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146: 873–887.
12. Bissell MJ, Hines WC. Why don't we get more cancer A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17: 320–329.
13. Fan F, Schimming A, Jaeger D, Podar K. Targeting the tumour microenvironment: focus on angiogenesis. J Oncol 2012; 2012: 281261.
14. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005; 97: 1093–1107.
15. Huijbers IJ, Iravani M, Popov S, Robertson D, Al-Sarraj S, Jones C et al. A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion. PLoS ONE 2010; 5: e9808.
16. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002; 295: 140–143.
17. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell 1997; 88: 277–285.
18. Giannelli G, Antonaci S. Biological and clinical relevance of laminin-5 in cancer. Clin Exp Metastasis 2000; 18: 439–443.
19. George EL, Baldwin HS, Hynes RO. Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood 1997; 90: 3073–3081.
20. Wijelath ES, Murray J, Rahman S, Patel Y, Ishida A, Strand K et al. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res 2002; 91: 25–31.
21. Yip GW, Smollich M, Gotte M. Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 2006; 5: 2139–2148.
22. Stern R. Hyaluronan in cancer biology. Semin Cancer Biol 2008; 18: 237.
23. Ye XZ, Yu SC, Bian XW. Contribution of myeloid-derived suppressor cells to tumour-induced immune suppression, angiogenesis, invasion and metastasis. J Genet Genomics 2010; 37: 423–430.
24. Rizzo M, Bayo J, Piccioni F, Malvicini M, Fiore E, Peixoto E et al. Low molecular weight hyaluronan-pulsed human dendritic cells showed increased migration capacity and induced resistance to tumour chemoattraction. PLoS ONE 2014; 9: e107944.
25. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265–277.
26. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C et al. The prognostic significance of intratumoural natural killer cells in patients with colorectal carcinoma. Cancer 1997; 79: 2320–2328.
27. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H et al. Prognostic value of intratumoural natural killer cells in gastric carcinoma. Cancer 2000; 88: 577–583.
28. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J et al. Prognostic significance of tumour infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002; 35: 23–28.
29. + B cells: the other tumour-infiltrating lymphocytes. J Immunol 2010; 185: 4977–4982.
30. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 2009; 4: e6412.
31. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008; 14: 5220–5227.
32. + T-cell infiltration in frequent and rare cancers. J Invest Dermatol 2013; 133: 1929–1932.
33. Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI. Hyaluronan in human tumours: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 2008; 18: 288–295.
34. Koyama H, Hibi T, Isogai Z, Yoneda M, Fujimori M, Amano J et al. Hyperproduction of hyaluronan in neu-induced mammary tumour accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol 2007; 170: 1086–1099.
35. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528–539.
36. Ghatak S, Misra S, Toole BP. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumour cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 2002; 277: 38013–38020.
37. Zeng C, Toole BP, Kinney SD, Kuo JW, Stamenkovic I. Inhibition of tumour growth in vivo by hyaluronan oligomers. Int J Cancer 1998; 77: 396–401.
38. Mueller BM, Schraufstatter IU, Goncharova V, Povaliy T, DiScipio R, Khaldoyanidi SK. Hyaluronan inhibits postchemotherapy tumour regrowth in a colon carcinoma xenograft model. Mol Cancer Ther 2010; 9: 3024–3032.
39. Berdiaki A, Nikitovic D, Tsatsakis A, Katonis P, Karamanos NK, Tzanakakis GN. bFGF induces changes in hyaluronan synthase and hyaluronidase isoform expression and modulates the migration capacity of fibrosarcoma cells. Biochim Biophys Acta 2009; 1790: 1258–1265.
40. Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature 2013; 499: 346–349.
41. Lee-Sayer SS, Dong Y, Arif AA, Olsson M, Brown KL, Johnson P. The where, when, how, and why of hyaluronan binding by immune cells. Front Immunol 2015; 6: 150.
42. Sokolowska M, Chen LY, Eberlein M, Martinez-Anton A, Liu Y, Alsaaty S et al. Low molecular weight hyaluronan activates cytosolic phospholipase A2alpha and eicosanoid production in monocytes and macrophages. J Biol Chem 2014; 289: 4470–4488.
43. Kobayashi N, Miyoshi S, Mikami T, Koyama H, Kitazawa M, Takeoka M et al. Hyaluronan deficiency in tumour stroma impairs macrophage trafficking and tumour neovascularization. Cancer Res 2010; 70: 7073–7083.
44. Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M et al. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002; 196: 204–212.
45. Murdoch C, Lewis CE. Macrophage migration and gene expression in response to tumour hypoxia. Int J Cancer 2005; 117: 701–708.
46. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW. Monocyte/macrophage infiltration in tumours: modulators of angiogenesis. J Leukoc Biol 2006; 80: 1183–1196.
47. Stockmann C, Schadendorf D, Klose R, Helfrich I. The impact of the immune system on tumour: angiogenesis and vascular remodeling. Front Oncol 2014; 4: 69.
48. Shen Z, Kauttu T, Seppanen H, Vainionpaa S, Ye Y, Wang S et al. Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs. Med Oncol 2012; 29: 2718–2726.
49. Klimp AH, Hollema H, Kempinga C, van der Zee AG. de Vries EG, Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumours and tumour-associated macrophages. Cancer Res 2001; 61: 7305–7309.
50. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004; 114: 623–633.
51. Hochst B, Schildberg FA, Sauerborn P, Gabel YA, Gevensleben H, Goltz D et al. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. J Hepatol 2013; 59: 528–535.
52. Alaniz L, Rizzo M, Garcia MG, Piccioni F, Aquino JB, Malvicini M et al. Low molecular weight hyaluronan preconditioning of tumour-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma. Cancer Immunol Immunother 2011; 60: 1383–1395.
53. Alaniz L, Rizzo M, Malvicini M, Jaunarena J, Avella D, Atorrasagasti C et al. Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumour cell proliferation and stimulating immune response. Cancer Lett 2009; 278: 9–16.
54. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195: 99–111.
55. Termeer CC, Hennies J, Voith U, Ahrens T, Weiss JM, Prehm P et al. Oligosaccharides of hyaluronan are potent activators of dendritic cells. J Immunol 2000; 165: 1863–1870.
56. Ricciardi A, Elia AR, Cappello P, Puppo M, Vanni C, Fardin P et al. Transcriptome of hypoxic immature dendritic cells: modulation of chemokine/receptor expression. Mol Cancer Res 2008; 6: 175–185.
57. Feijoo E, Alfaro C, Mazzolini G, Serra P, Penuelas I, Arina A et al. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 2005; 116: 275–281.
58. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150–4166.
59. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942–949.
60. Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ et al. Tumour-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004; 10: 950–958.
61. Gottfried E, Kreutz M, Haffner S, Holler E, Iacobelli M, Andreesen R et al. Differentiation of human tumour-associated dendritic cells into endothelial-like cells: an alternative pathway of tumour angiogenesis. Scand J Immunol 2007; 65: 329–335.
62. Okunishi K, Dohi M, Nakagome K, Tanaka R, Mizuno S, Matsumoto K et al. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol 2005; 175: 4745–4753.
63. Alard P, Clark SL, Kosiewicz MM. Mechanisms of tolerance induced by TGF beta-treated APC: CD4 regulatory T cells prevent the induction of the immune response possibly through a mechanism involving TGF beta. Eur J Immunol 2004; 34: 1021–1030.
64. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004; 11: 328–339.
65. Puig-Kroger A, Pello OM, Selgas R, Criado G, Bajo MA, Sanchez-Tomero JA et al. Peritoneal dialysis solutions inhibit the differentiation and maturation of human monocyte-derived dendritic cells: effect of lactate and glucose-degradation products. J Leukoc Biol 2003; 73: 482–492.
66. Konno S, Eckman JA, Plunkett B, Li X, Berman JS, Schroeder J et al. Interleukin-10 and Th2 cytokines differentially regulate osteopontin expression in human monocytes and dendritic cells. J Interferon Cytokine Res 2006; 26: 562–567.
67. Sague SL, Tato C, Pure E, Hunter CA. The regulation and activation of CD44 by natural killer (NK) cells and its role in the production of IFN-gamma. J Interferon Cytokine Res 2004; 24: 301–309.
68. Zhang J, Chen Z, Smith GN, Croy BA. Natural killer cell-triggered vascular transformation: maternal care before birth? Cell Mol Immunol 2011; 8: 1–11.
69. Bruno A, Focaccetti C, Pagani A, Imperatori AS, Spagnoletti M, Rotolo N et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia 2013; 15: 133–142.
70. Rafi A, Nagarkatti M, Nagarkatti PS. Hyaluronate-CD44 interactions can induce murine B-cell activation. Blood 1997; 89: 2901–2908.
71. Yang C, Lee H, Pal S, Jove V, Deng J, Zhang W et al. B cells promote tumour progression via STAT3 regulated-angiogenesis. PLoS ONE 2013; 8: e64159.
72. Bohrer LR, Chuntova P, Bade LK, Beadnell TC, Leon RP, Brady NJ et al. Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumour formation. Cancer Res 2014; 74: 374–386.
73. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475: 226–230.
74. Pober JS, Tellides G. Participation of blood vessel cells in human adaptive immune responses. Trends Immunol 2012; 33: 49–57.
75. Choi J, Enis DR, Koh KP, Shiao SL, Pober JS. T lymphocyte–endothelial cell interactions. Annu Rev Immunol 2004; 22: 683–709.
76. + T cells. Proc Natl Acad Sci USA 1994; 91: 2890–2894.
77. Fathallah-Shaykh HM, Zhao LJ, Kafrouni AI, Smith GM, Forman J. Gene transfer of IFN-gamma into established brain tumours represses growth by antiangiogenesis. J Immunol 2000; 164: 217–222.
78. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R et al. An evaluation of tumour oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006; 12: 1507–1514.
79. Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int 2006; 56: 62–70.
80. Watanabe O, Kinoshita J, Shimizu T, Imamura H, Hirano A, Okabe T et al. Expression of a CD44 variant and VEGF-C and the implications for lymphatic metastasis and long-term prognosis of human breast cancer. J Exp Clin Cancer Res 2005; 24: 75–82.
81. Zavrides HN, Zizi-Sermpetzoglou A, Panousopoulos D, Athanasas G, Elemenoglou I, Peros G. Prognostic evaluation of CD44 expression in correlation with bcl-2 and p53 in colorectal cancer. Folia Histochem Cytobiol 2005; 43: 31–36.
82. Lai CH, Shan YS, Sy ED, Hsieh YH, Tsai HW, Lee JC et al. The significance of CD44 expression in gastrointestinal neuroendocrine tumours. Hepatogastroenterology 2005; 52: 1071–1076.
83. Bourguignon LY. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumour progression. Semin Cancer Biol 2008; 18: 251–259.
84. Singleton PA, Dudek SM, Ma SF, Garcia JG. Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. J Biol Chem 2006; 281: 34381–34393.
85. Bokoch GM. Regulation of innate immunity by Rho GTPases. Trends Cell Biol 2005; 15: 163–171.
86. Ghatak S, Misra S, Toole BP. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 2005; 280: 8875–8883.
87. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29–86.
88. Alaniz L, Garcia MG, Gallo-Rodriguez C, Agusti R, Sterin-Speziale N, Hajos SE et al. Hyaluronan oligosaccharides induce cell death through PI3-K/Akt pathway independently of NF-kappaB transcription factor. Glycobiology 2006; 16: 359–367.
89. Karar J, Maity A. PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci 2011; 4: 51.
90. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 2013; 31: 675–704.
91. Bourguignon LY, Gilad E, Peyrollier K. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumour cell growth and migration. J Biol Chem 2007; 282: 19426–19441.
92. Bourguignon LY, Peyrollier K, Gilad E, Brightman A. Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumour cells. J Biol Chem 2007; 282: 1265–1280.
93. Daugherty RL, Gottardi CJ. Phospho-regulation of Beta-catenin adhesion and signaling functions. Physiology (Bethesda) 2007; 22: 303–309.
94. Schade B, Lesurf R, Sanguin-Gendreau V, Bui T, Deblois G, O'Toole SA et al. beta-Catenin signaling is a critical event in ErbB2-mediated mammary tumour progression. Cancer Res 2013; 73: 4474–4487.
95. Franco CA, Liebner S, Gerhardt H. Vascular morphogenesis: a Wnt for every vessel? Curr Opin Genet Dev 2009; 19: 476–483.
96. Chang G, Zhang H, Wang J, Zhang Y, Xu H, Wang C et al. CD44 targets Wnt/beta-catenin pathway to mediate the proliferation of K562 cells. Cancer Cell Int 2013; 13: 117.
97. Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001; 61: 6050–6054.
98. Masckauchan TN, Shawber CJ, Funahashi Y, Li CM, Kitajewski J. Wnt/beta-catenin signaling induces proliferation, survival and interleukin-8 in human endothelial cells. Angiogenesis 2005; 8: 43–51.
99. Jones M, Tussey L, Athanasou N, Jackson DG. Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. J Biol Chem 2000; 275: 7964–7974.
100. Ramachandran I, Thavathiru E, Ramalingam S, Natarajan G, Mills WK, Benbrook DM et al. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. Oncogene 2012; 31: 2725–2737.
101. Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J et al. BCL9 promotes tumour progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 2009; 69: 7577–7586.
102. Gattinoni L, Ji Y, Restifo NP. Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. Clin Cancer Res 2010; 16: 4695–4701.
103. Swafford D, Manicassamy S. Wnt signaling in dendritic cells: its role in regulation of immunity and tolerance. Discov Med 2015; 19: 303–310.
104. Abecassis I, Olofsson B, Schmid M, Zalcman G, Karniguian A. RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp Cell Res 2003; 291: 363–376.
105. Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E. CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumour cell invasion. J Biol Chem 2004; 279: 26991–27007.
106. Lokeshwar VB, Iida N, Bourguignon LY. The cell adhesion molecule, GP116, is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation. J Biol Chem 1996; 271: 23853–23864.
107. Marrero-Diaz R, Bravo-Cordero JJ, Megias D, Garcia MA, Bartolome RA, Teixido J et al. Polarized MT1-MMP-CD44 interaction and CD44 cleavage during cell retraction reveal an essential role for MT1-MMP in CD44-mediated invasion. Cell Motil Cytoskeleton 2009; 66: 48–61.
108. Lokeshwar VB, Mirza S, Jordan A. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res 2014; 123: 35–65.
109. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumours. J Cell Biol 2005; 169: 681–691.
110. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumour invasion and angiogenesis. Genes Dev 2000; 14: 163–176.
111. Fieber C, Baumann P, Vallon R, Termeer C, Simon JC, Hofmann M et al. Hyaluronan-oligosaccharide-induced transcription of metalloproteases. J Cell Sci 2004; 117: 359–367.
112. Noble PW, McKee CM, Cowman M, Shin HS. Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha autoregulatory loop in murine macrophages. J Exp Med 1996; 183: 2373–2378.
113. Voelcker V, Gebhardt C, Averbeck M, Saalbach A, Wolf V, Weih F et al. Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol 2008; 17: 100–107.
114. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004; 279: 17079–17084.
115. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumourigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000; 60: 5334–5339.
116. Maxwell CA, McCarthy J, Turley E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci 2008; 121: 925–932.
117. Eck M, Schmausser B, Scheller K, Brandlein S, Muller-Hermelink HK. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin Exp Immunol 2003; 134: 508–515.
118. Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C et al. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 2007; 282: 16667–16680.
119. Adamia S, Kriangkum J, Belch AR, Pilarski LM. Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumour progression. Adv Cancer Res 2014; 123: 67–94.
120. Masellis-Smith A, Belch AR, Mant MJ, Turley EA, Pilarski LM. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44. Blood 1996; 87: 1891–1899.
121. Slevin M, Krupinski J, Gaffney J, Matou S, West D, Delisser H et al. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol 2007; 26: 58–68.
122. Savani RC, Cao G, Pooler PM, Zaman A, Zhou Z, DeLisser HM. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J Biol Chem 2001; 276: 36770–36778.
123. Matou-Nasri S, Gaffney J, Kumar S, Slevin M. Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin. Int J Oncol 2009; 35: 761–773.
124. Hirota K, Semenza GL. Rac1 activity is required for the activation of hypoxia-inducible factor 1. J Biol Chem 2001; 276: 21166–21172.
125. Park D, Kim Y, Kim H, Kim K, Lee YS, Choe J et al. Hyaluronic acid promotes angiogenesis by inducing RHAMM-TGFbeta receptor interaction via CD44-PKCdelta. Mol Cells 2012; 33: 563–574.
126. Zaman A, Cui Z, Foley JP, Zhao H, Grimm PC, Delisser HM et al. Expression and role of the hyaluronan receptor RHAMM in inflammation after bleomycin injury. Am J Respir Cell Mol Biol 2005; 33: 447–454.
127. Kim WY, Lee HY. Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumours. FEBS J 2009; 276: 4653–4664.
128. Garber K. Angiogenesis inhibitors suffer new setback. Nat Biotechnol 2002; 20: 1067–1068.
129. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumour growth. Nat Med 2002; 8: 1369–1375.
130. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001; 414: 550–554.
131. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422–5428.